H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $90 from $80 and keeps a Buy rating on the shares. The company reported positive results from its Phase 3 study of encaleret in autosomal dominant hypocalcemia type 1, the analyst tells investors in a research note. The firm upped its probability of approval to 90% from 80% and believes encaleret could be submitted for approval to the FDA during the first half of 2026 with market entry either in late 2026 or early 2027.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio announces Phase 3 study of encaleret met primary endpoint
- Optimistic Buy Rating for BridgeBio Pharma: Promising Phase 3 Trial Results and Future Developments
- BridgeBio price target raised to $76 from $58 at BofA
- BridgeBio price target raised to $80 from $70 at H.C. Wainwright
- Positive Outlook for BridgeBio Pharma: Buy Rating Affirmed on Strong Phase 3 Trial Results and Strategic Market Positioning